11 October 2024 
ImmunOs Therapeutics AG, in Schlieren, a biopharmaceutical company developing first-in-class therapeutics for the treatment of cancer and autoimmune diseases based on its unique immune system modulating technology platform, closed a Series C financing round.
Proceeds from the Series C will be used to further fund the ongoing clinical trial of ImmunOs’ lead program IOS-1002.
VISCHER advised ImmunOs Therapeutics AG on all legal issues related to the transaction. The VISCHER team includes Christian Wyss, Pauline Pfirter, Lucas M. Sturzenegger and Lionel Battegay (all Corporate / M&A).
Author: Christian Wyss